Syracuse

Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition

Archive ouverte

Comsa, Elisabeta | Nguyen, Kim-Anh | Loghin, Felicia | Boumendjel, Ahcène | Peuchmaur, Marine | Andrieu, Thibault | Falson, Pierre

Edité par CCSD ; Future Science -

International audience. Aim: Cisplatin resistance in ovarian cancer remains a complex problem as tumors frequently develop resistance against drugs, a mechanism sometimes mediated by ATP-Binding Cassette transporters. Our goal was to find compounds restricting their inhibition capacity to the cisplatin efflux mediated by ABCC2 pump, among previously identified inhibitors, derived from the 2-indolylmethylenebenzofuranones. Methodology & results: An original method setup allows direct quantitation of platinum by employing cyTOF mass cytometry. Among tested derivatives, some led to a full platinum accumulation and efficiently resensitized cisplatin-resistant A2780 cells to cisplatin while preserving most of the calcein efflux activity. Conclusion: CyTOF is therefore a powerful and promising method to quantify cisplatin accumulation that may be used in the clinical setting to improve and personalize cancer treatment.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion